BAX - Baxter International Inc.

NYSE - NYSE Delayed Price. Currency in USD
77.18
-0.41 (-0.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close77.59
Open77.68
Bid77.05 x 800
Ask77.70 x 800
Day's Range76.87 - 77.74
52 Week Range61.05 - 78.38
Volume2,035,576
Avg. Volume3,281,193
Market Cap39.558B
Beta (3Y Monthly)1.09
PE Ratio (TTM)25.91
EPS (TTM)2.98
Earnings DateApr 25, 2019
Forward Dividend & Yield0.76 (0.98%)
Ex-Dividend Date2019-02-28
1y Target Est79.59
Trade prices are not sourced from all markets
  • GuruFocus.comyesterday

    Morgan Stanley Institutional Global Franchise Fund Buys Baxter International Inc, Heineken NV

    Investment company Morgan Stanley Institutional Global Franchise Fund buys Baxter International Inc, Heineken NV during the 3-months ended 2018Q4, according to the most recent filings of the investment ...

  • Top Analyst Reports for Home Depot, Oracle & Union Pacific
    Zacksyesterday

    Top Analyst Reports for Home Depot, Oracle & Union Pacific

    Top Analyst Reports for Home Depot, Oracle & Union Pacific

  • Baxter (BAX) Upgraded to Buy: Here's What You Should Know
    Zacksyesterday

    Baxter (BAX) Upgraded to Buy: Here's What You Should Know

    Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
    Zacks2 days ago

    Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

    Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

  • Business Wire2 days ago

    Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury

    Baxter International Inc. (BAX), a global leader in acute care, and bioMérieux, a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). The announcement was made at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week.

  • Could Baxter International Inc.’s (NYSE:BAX) Investor Composition Influence The Stock Price?
    Simply Wall St.4 days ago

    Could Baxter International Inc.’s (NYSE:BAX) Investor Composition Influence The Stock Price?

    Every investor in Baxter International Inc. (NYSE:BAX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Baxter International Inc.

    Baxter International Inc NYSE:BAXView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for BAX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BAX had net inflows of $3.16 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BAX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
    Zacks14 days ago

    Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS

    Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.

  • Business Wire15 days ago

    Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide

    Baxter International Inc. (BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval and launch of ready-to-use eptifibatide. Baxter’s presentation of eptifibatide is the first of its kind available in a flexible container.

  • GlobeNewswire15 days ago

    Analysis: Positioning to Benefit within XPO Logistics, L3 Technologies, Domino's Pizza, Baxter International, Conduent, and Xylem — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire16 days ago

    Baxter Honored as a 2019 “Top Company for Executive Women” by the National Association for Female Executives

    Baxter International Inc. (BAX), a leading global medical products company, announced today that it has been named one of the 2019 NAFE Top Companies for Executive Women by the National Association for Female Executives (NAFE). This recognition highlights the company’s efforts to advance women in leadership and foster an inclusive and diverse culture.

  • If You Had Bought Baxter International Shares Three Years Ago You’d Have Made 89%
    Simply Wall St.19 days ago

    If You Had Bought Baxter International Shares Three Years Ago You’d Have Made 89%

    By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual stocks, you could make more than that. For example,Read More...

  • Dan Loeb’s Third Point Looks to Baxter and Campbell Soup in 2019
    Market Realist20 days ago

    Dan Loeb’s Third Point Looks to Baxter and Campbell Soup in 2019

    How Dan Loeb Hopes to Improve Third Point's Performance in 2019(Continued from Prior Part)Baxter InternationalDuring Q4 2018, Third Point reduced its stake by ~33% in healthcare company Baxter International (BAX). It is still the largest single

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of BAX earnings conference call or presentation 31-Jan-19 1:30pm GMT

    Q4 2018 Baxter International Inc Earnings Call

  • GuruFocus.com26 days ago

    Daniel Loeb Comments on Baxter

    Baxter (NYSE:BAX) remains the firm's largest position and Third Point Partner and Head of Equities Munib Islam serves on the Board of Directors. In past quarterly letters, we detailed our initial investment thesis and highlighted the extraordinary transformation that CEO Joe Almeida has overseen at the company since joining at the end of 2015. Warning! GuruFocus has detected 6 Warning Signs with BAX.

  • Reuters26 days ago

    U.S. closes IV solution shortage antitrust probe, Baxter says

    Baxter International Inc said the U.S. Justice Department has closed an antitrust probe examining possible communication among producers of intravenous saline solutions during supply shortages that created higher prices. Baxter, which received a grand jury subpoena in 2017 as part of the investigation, said in a filing with the U.S. Securities and Exchange Commission on Thursday that the department informed it on Nov. 30 of its decision to end the probe. Other companies that in April 2017 disclosed receiving subpoenas as part of the investigation included Pfizer Inc and ICU Medical Inc, which earlier that year had acquired Pfizer's global infusion therapy business.

  • GuruFocus.com27 days ago

    Baxter International Inc (BAX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Baxter International Inc operates in the healthcare industry. The dividend yield of Baxter International Inc stocks is 0.98%. Baxter International Inc had annual average EBITDA growth of 0.40% over the past ten years.

  • Business Wirelast month

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per share of common stock. The indicated annual dividend rate is $0.76 per share of common stock. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

  • Does Baxter International Inc. (NYSE:BAX) Have A Good P/E Ratio?
    Simply Wall St.last month

    Does Baxter International Inc. (NYSE:BAX) Have A Good P/E Ratio?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is for investors who wouldRead More...

  • Baxter's Acute Therapies Profile Strong, Competition Rife
    Zackslast month

    Baxter's Acute Therapies Profile Strong, Competition Rife

    Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

  • Business Wirelast month

    Baxter to Present at the Barclays Global Healthcare Conference

    Baxter International Inc. , a leading global medical products company, will present at the Barclays Global Healthcare Conference in Miami, Fla. on March 12, 2019. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 3:20 p.m.

  • Dan Loeb Increased Third Point’s Position in These Stocks in Q4
    Market Realistlast month

    Dan Loeb Increased Third Point’s Position in These Stocks in Q4

    Dan Loeb's Third Point Had a Weak 2018: Will 2019 Be Any Better?(Continued from Prior Part)Third Point’s only new position In Q4 2018, Third Point initiated a new position in Cigna (CI), which is an American healthcare services organization. Hike

  • Baxter and NantHealth® Advance Digital Health Technology for Medical Devices in the Hospital ICU
    Business Wirelast month

    Baxter and NantHealth® Advance Digital Health Technology for Medical Devices in the Hospital ICU

    @baxter_intl and @NantHealth advance DigitalHealth technology for medical devices in the hospital ICU #CriticalCare #HIMSS19